Abstract
The simpler, the better: H(3) histamine receptor (H(3)R) are of interest as therapeutic targets in cognitive and somnolence disorders. Here, lead optimization of H(3)R inverse agonists bearing a thiazolo[5,4-c]piperidine group gave rise to a clinical candidate with a much simpler unprecedented benzamide scaffold, displaying decreased hERG activity while maintaining high brain receptor occupancies.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Benzamides / chemistry
-
Benzamides / pharmacokinetics
-
Benzamides / pharmacology
-
Caco-2 Cells
-
Histamine Agonists / chemistry*
-
Histamine Agonists / pharmacokinetics
-
Histamine Agonists / pharmacology*
-
Humans
-
Male
-
Piperidines / chemistry*
-
Piperidines / pharmacokinetics
-
Piperidines / pharmacology*
-
Rats
-
Rats, Wistar
-
Receptors, Histamine H3 / metabolism*
-
Structure-Activity Relationship
-
Thiazoles / chemistry
-
Thiazoles / pharmacokinetics
-
Thiazoles / pharmacology
-
Trans-Activators / metabolism
-
Transcriptional Regulator ERG
Substances
-
Benzamides
-
ERG protein, human
-
Histamine Agonists
-
Piperidines
-
Receptors, Histamine H3
-
Thiazoles
-
Trans-Activators
-
Transcriptional Regulator ERG